Loading...
Header Logo
Keywords
Last Name
Institution

CONSTANCE ALBARRACIN

TitleProfessor
InstitutionMD Anderson
DepartmentPathology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM. Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg. 2019 Jan; 269(1):150-157. PMID: 28742682.
      View in: PubMed
    2. Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res. 2018 12 11; 20(1):150. PMID: 30537987.
      View in: PubMed
    3. Clifton K, Gutierrez-Barrera A, Ma J, Bassett R, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018 Jul; 170(1):101-109. PMID: 29470805.
      View in: PubMed
    4. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017; 8(14):2653-2662. PMID: 28928852.
      View in: PubMed
    5. Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RF. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. 2018 01; 24(1):28-34. PMID: 28608612.
      View in: PubMed
    6. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. PMID: 27893038.
      View in: PubMed
    7. Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget. 2017 02 14; 8(7):10845-10857. PMID: 28125801.
      View in: PubMed
    8. Menen RS, Ganesan N, Bevers T, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian I. Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Ann Surg Oncol. 2017 Jan; 24(1):70-76. PMID: 27573525.
      View in: PubMed
    9. Raj SD, Sahani VG, Adrada BE, Scoggins ME, Albarracin CT, Woodtichartpreecha P, Posleman Monetto FE, Whitman GJ. Pseudoangiomatous Stromal Hyperplasia of the Breast: Multimodality Review With Pathologic Correlation. Curr Probl Diagn Radiol. 2017 Mar - Apr; 46(2):130-135. PMID: 26949063.
      View in: PubMed
    10. Miller T, Albarracin C, Carkaci S, Whitman GJ, Adrada BE. Rare Malignant Tumors of the Breast. J Clin Imaging Sci. 2015; 5:58. PMID: 26664775.
      View in: PubMed
    11. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015 Oct 01; 121(19):3422-7. PMID: 26280679; PMCID: PMC4829956 [Available on 10/01/16].
    12. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2015 Jun 25; 17:87. PMID: 26108797; PMCID: PMC4480452.
    13. Bhardwaj A, Ganesan N, Tachibana K, Rajapakshe K, Albarracin CT, Gunaratne PH, Coarfa C, Bedrosian I. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling. PLoS One. 2015; 10(5):e0127678. PMID: 26000884.
      View in: PubMed
    14. Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez RH, Kantarjian HM, Mego M, Albarracin C, Tang G, Strom SS, Medeiros LJ, Hortobagyi GN, Reuben JM, Khoury JD. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia. 2016 Jan; 30(1):242-7. PMID: 25975189.
      View in: PubMed
    15. Peintinger F, Sinn B, Hatzis C, Albarracin C, Downs-Kelly E, Morkowski J, Gould R, Symmans WF. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol. 2015 Jul; 28(7):913-20. PMID: 25932963; PMCID: PMC4830087.
    16. Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015 Jul; 26(7):1346-52. PMID: 25878190.
      View in: PubMed
    17. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015 Jun 01; 21(11):2580-90. PMID: 25739674.
      View in: PubMed
    18. Xiang DB, Wei B, Abraham SC, Huo L, Albarracin CT, Zhang H, Babiera G, Caudle AS, Akay CL, Rao P, Zhao YJ, Lu X, Wu Y. Molecular cytogenetic characterization of mammary neuroendocrine carcinoma. Hum Pathol. 2014 Sep; 45(9):1951-6. PMID: 25074542.
      View in: PubMed
    19. Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I. Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis. PLoS One. 2014; 9(5):e97076. PMID: 24811059; PMCID: PMC4014598.
    20. Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014 Oct; 21(11):3466-72. PMID: 24796968; PMCID: PMC4224140.
    21. Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014 Mar 04; 14:147. PMID: 24589259; PMCID: PMC3974013.
    22. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2014; 16(6):3417. PMID: 25551582; PMCID: PMC4326485.
    23. Krishnamurthy S, Mathews K, McClure S, Murray M, Gilcrease M, Albarracin C, Spinosa J, Chang B, Ho J, Holt J, Cohen A, Giri D, Garg K, Bassett RL, Liang K. Multi-institutional comparison of whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sections. Arch Pathol Lab Med. 2013 Dec; 137(12):1733-9. PMID: 23947655.
      View in: PubMed
    24. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol. 2012 Sep; 36(9):1353-8. PMID: 22895267.
      View in: PubMed
    25. Li X, Deavers MT, Guo M, Liu P, Gong Y, Albarracin CT, Middleton LP, Huo L. The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer. Mod Pathol. 2013 Jan; 26(1):71-8. PMID: 22899286; PMCID: PMC3881416.
    26. Geyer FC, Lacroix-Triki M, Colombo PE, Patani N, Gauthier A, Natrajan R, Lambros MB, Khalifeh I, Albarracin C, Orru S, Marchiò C, Sapino A, Mackay A, Weigelt B, Schmitt FC, Wesseling J, Sneige N, Reis-Filho JS. Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology. 2012 May; 60(6B):E115-30. PMID: 22486256.
      View in: PubMed
    27. Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Fuller GN. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Ann Diagn Pathol. 2012 Aug; 16(4):255-9. PMID: 22445362.
      View in: PubMed
    28. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41. PMID: 22392043; PMCID: PMC3855009.
    29. Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, Hung MC, Fan Z. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene. 2012 Oct 04; 31(40):4372-83. PMID: 22231447; PMCID: PMC3326223.
    30. Olar A, Raghunathan A, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Goodman JC, Fuller GN. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Ann Diagn Pathol. 2012 Jun; 16(3):161-70. PMID: 22197544.
      View in: PubMed
    31. Perry KD, Reynolds C, Rosen DG, Edgerton ME, T Albarracin C, Gilcrease MZ, Sahin AA, Abraham SC, Wu Y. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology. 2011 Oct; 59(4):619-30. PMID: 22014043.
      View in: PubMed
    32. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 01; 29(28):3739-46. PMID: 21900106; PMCID: PMC4874218.
    33. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012 Mar 15; 118(6):1515-22. PMID: 22009639; PMCID: PMC4407692.
    34. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011 Nov; 130(1):145-53. PMID: 21830012; PMCID: PMC4334122.
    35. Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology. 2011 Jul; 59(1):106-15. PMID: 21668471.
      View in: PubMed
    36. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):e572-5. PMID: 21482991.
      View in: PubMed
    37. Shehu A, Albarracin C, Devi YS, Luther K, Halperin J, Le J, Mao J, Duan RW, Frasor J, Gibori G. The stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells. Mol Endocrinol. 2011 May; 25(5):754-66. PMID: 21372145; PMCID: PMC3082328.
    38. Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol. 2011 Aug; 42(8):1169-77. PMID: 21334720.
      View in: PubMed
    39. Whitman GJ, Albarracin CT, Gonzalez-Angulo AM. Triple-negative breast cancer: what the radiologist needs to know. Semin Roentgenol. 2011 Jan; 46(1):26-39. PMID: 21134526.
      View in: PubMed
    40. Albarracin CT, Nguyen CV, Whitman GJ, Yang W, Weiang W, Sneige N. Identifying patients with atypical ductal hyperplasia diagnosed at core-needle biopsy who are at low risk of malignancy. Radiology. 2010 Dec; 257(3):893-4; author reply 984. PMID: 21084420.
      View in: PubMed
    41. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell. 2010 Nov 16; 18(5):423-35. PMID: 21075308; PMCID: PMC3022383.
    42. Resetkova E, Khazai L, Albarracin CT, Arribas E. Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast. Breast J. 2010 Nov-Dec; 16(6):573-80. PMID: 21070433.
      View in: PubMed
    43. Nguyen CV, Albarracin CT, Whitman GJ, Lopez A, Sneige N. Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision. Ann Surg Oncol. 2011 Mar; 18(3):752-61. PMID: 20972636.
      View in: PubMed
    44. Wu X, Chen F, Sahin A, Albarracin C, Pei Z, Zou X, Singh B, Xu R, Daniels G, Li Y, Wei J, Blake M, Schneider RJ, Cowin P, Lee P. Distinct function of androgen receptor coactivator ARA70a and ARA70ß in mammary gland development, and in breast cancer. Breast Cancer Res Treat. 2011 Jul; 128(2):391-400. PMID: 20814820.
      View in: PubMed
    45. Dawood S, Gonzalez-Angulo AM, Albarracin C, Yu TK, Hortobagyi GN, Buchholz TA, Woodward WA. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer. 2010 Jul 01; 116(13):3084-92. PMID: 20564633; PMCID: PMC3041268.
    46. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med. 2010 Feb; 134(2):162-3; author reply 163. PMID: 20121597.
      View in: PubMed
    47. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009 Dec; 20(12):1953-8. PMID: 19596702; PMCID: PMC2791352.
    48. Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol. 2009 Apr; 33(4):534-41. PMID: 19047898.
      View in: PubMed
    49. Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, Romans AM, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A, Luthra R. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009 May; 174(5):1940-8. PMID: 19342367; PMCID: PMC2671281.
    50. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila). 2009 Feb; 2(2):122-7. PMID: 19174581; PMCID: PMC4520422.
    51. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009 Apr; 20(4):621-7. PMID: 19150943; PMCID: PMC2722369.
    52. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88. PMID: 19064970.
      View in: PubMed
    53. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol. 2008 Dec; 16(6):530-4. PMID: 18776816.
      View in: PubMed
    54. Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 2009 Jan 10; 27(2):220-6. PMID: 19047281; PMCID: PMC4516695.
    55. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008 Sep 10; 26(26):4282-8. PMID: 18779615.
      View in: PubMed
    56. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008 Sep; 47(9):701-6. PMID: 18176935; PMCID: PMC2580832.
    57. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM, Broaddus RR, Rashid A, Albarracin CT. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008 Nov 06; 27(52):6667-78. PMID: 18663355.
      View in: PubMed
    58. Resetkova E, Edelweiss M, Albarracin CT, Yang WT. Management of radial sclerosing lesions of the breast diagnosed using percutaneous vacuum-assisted core needle biopsy: recommendations for excision based on seven years' of experience at a single institution. Breast Cancer Res Treat. 2011 Jun; 127(2):335-43. PMID: 18626769.
      View in: PubMed
    59. Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Am J Surg Pathol. 2008 Apr; 32(4):544-52. PMID: 18300793.
      View in: PubMed
    60. Ferreira M, Albarracin CT, Resetkova E. Pseudoangiomatous stromal hyperplasia tumor: a clinical, radiologic and pathologic study of 26 cases. Mod Pathol. 2008 Feb; 21(2):201-7. PMID: 18084246.
      View in: PubMed
    61. Gokhale S, Rosen D, Sneige N, Diaz LK, Resetkova E, Sahin A, Liu J, Albarracin CT. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol. 2007 Dec; 15(4):451-5. PMID: 18091390.
      View in: PubMed
    62. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Yang W, Albarracin C, Meric F, Hortobagyi G, Theriault R. Development of new cancers in patients with DCIS: the M.D. Anderson experience. Ann Surg Oncol. 2008 Jan; 15(1):244-9. PMID: 18043978.
      View in: PubMed
    63. May SA, Deavers MT, Resetkova E, Johnson D, Albarracin CT. Giant cell tumor of soft tissue arising in breast. Ann Diagn Pathol. 2007 Oct; 11(5):345-9. PMID: 17870021.
      View in: PubMed
    64. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007 Feb 15; 109(4):658-67. PMID: 17211865.
      View in: PubMed
    65. He J, Pan Y, Hu J, Albarracin C, Wu Y, Dai JL. Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther. 2007 Jan; 6(1):76-82. PMID: 17172821.
      View in: PubMed
    66. Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetkova E. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer. 2006 Oct 15; 107(8):1760-8. PMID: 16977650.
      View in: PubMed
    67. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res. 2006 Aug 01; 12(15):4598-604. PMID: 16899607.
      View in: PubMed
    68. Anderson P, Albarracin CT, Resetkova E. A large, fungating breast mass. Secretory carcinoma with apocrine differentiation. Arch Pathol Lab Med. 2006 Apr; 130(4):e50-2. PMID: 16594759.
      View in: PubMed
    69. Resetkova E, Albarracin C, Sneige N. Collagenous spherulosis of breast: morphologic study of 59 cases and review of the literature. Am J Surg Pathol. 2006 Jan; 30(1):20-7. PMID: 16330938.
      View in: PubMed
    70. Chang KH, Albarracin C, Luthra R, Wang L, Zheng W, Malpica A, Deavers MT, Silva EG, Liu J. Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis. Int J Gynecol Cancer. 2006 Jan-Feb; 16(1):178-82. PMID: 16445630.
      View in: PubMed
    71. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer. 2005 Dec; 12(4):1059-69. PMID: 16322343.
      View in: PubMed
    72. Albarracin CT, Silva EG, Malpica A, Luthra R, Liu J. The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and relationship with microsatellite instability phenotype. Oncol Rep. 2004 Dec; 12(6):1217-9. PMID: 15547740.
      View in: PubMed
    73. Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, Meric-Bernstam F, Marcelo Aldaz C, Marcelo AC, Hortobagyi GN, Pusztai L. Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat. 2004 Oct; 87(3):205-14. PMID: 15528963.
      View in: PubMed
    74. Cai KQ, Albarracin C, Rosen D, Zhong R, Zheng W, Luthra R, Broaddus R, Liu J. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 2004 May; 35(5):552-9. PMID: 15138928.
      View in: PubMed
    75. Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, Zheng W, Gershenson DM, Broaddus R, Luthra R. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol. 2004 Jan; 17(1):75-80. PMID: 14631366.
      View in: PubMed
    76. Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol. 2000 Jun; 31(6):672-7. PMID: 10872659.
      View in: PubMed
    77. Albarracin CT, Frosch MP, Chin WW. The gonadotropin-releasing hormone receptor gene promoter directs pituitary-specific oncogene expression in transgenic mice. Endocrinology. 1999 May; 140(5):2415-21. PMID: 10218996.
      View in: PubMed
    78. Albarracin C, Rosencrance G, Boland J, Hernandez JE. Bacteremia due to streptococcus zooepidemicus associated with an abdominal aortic aneurysm. W V Med J. 1998 Mar-Apr; 94(2):90-2. PMID: 9581510.
      View in: PubMed
    79. Telleria CM, Parmer TG, Zhong L, Clarke DL, Albarracin CT, Duan WR, Linzer DI, Gibori G. The different forms of the prolactin receptor in the rat corpus luteum: developmental expression and hormonal regulation in pregnancy. Endocrinology. 1997 Nov; 138(11):4812-20. PMID: 9348210.
      View in: PubMed
    80. Duan WR, Parmer TG, Albarracin CT, Zhong L, Gibori G. PRAP, a prolactin receptor associated protein: its gene expression and regulation in the corpus luteum. Endocrinology. 1997 Aug; 138(8):3216-21. PMID: 9231770.
      View in: PubMed
    81. Fernández-Vázquez G, Kaiser UB, Albarracin CT, Chin WW. Transcriptional activation of the gonadotropin-releasing hormone receptor gene by activin A. Mol Endocrinol. 1996 Apr; 10(4):356-66. PMID: 8721981.
      View in: PubMed
    82. Merola C, Albarracin C, Lebowitz P, Bienkowski RS, Barst SM. An audit of adverse events in children sedated with chloral hydrate or propofol during imaging studies. Paediatr Anaesth. 1995; 5(6):375-8. PMID: 8597970.
      View in: PubMed
    83. Albarracin CT, Kaiser UB, Chin WW. Isolation and characterization of the 5'-flanking region of the mouse gonadotropin-releasing hormone receptor gene. Endocrinology. 1994 Dec; 135(6):2300-6. PMID: 7988412.
      View in: PubMed
    84. Mao J, Duan WR, Albarracin CT, Parmer TG, Gibori G. Isolation and characterization of a rat luteal cDNA encoding 20 alpha-hydroxysteroid dehydrogenase. Biochem Biophys Res Commun. 1994 Jun 30; 201(3):1289-95. PMID: 8024573.
      View in: PubMed
    85. Albarracin CT, Parmer TG, Duan WR, Nelson SE, Gibori G. Identification of a major prolactin-regulated protein as 20 alpha-hydroxysteroid dehydrogenase: coordinate regulation of its activity, protein content, and messenger ribonucleic acid expression. Endocrinology. 1994 Jun; 134(6):2453-60. PMID: 8194472.
      View in: PubMed
    86. Albarracin CT, Palfrey HC, Duan WR, Rao MC, Gibori G. Prolactin regulation of the calmodulin-dependent protein kinase III elongation factor-2 system in the rat corpus luteum. J Biol Chem. 1994 Mar 11; 269(10):7772-6. PMID: 8126003.
      View in: PubMed
    87. Parmer TG, McLean MP, Duan WR, Nelson SE, Albarracin CT, Khan I, Gibori G. Hormonal and immunological characterization of the 32 kilodalton ovarian-specific protein. Endocrinology. 1992 Nov; 131(5):2213-21. PMID: 1425419.
      View in: PubMed
    88. Sotomayor EM, Fu YX, Lopez-Cepero M, Herbert L, Jimenez JJ, Albarracin C, Lopez DM. Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J Immunol. 1991 Oct 15; 147(8):2816-23. PMID: 1918995.
      View in: PubMed
    89. Albarracin CT, Gibori G. Prolactin action on luteal protein expression in the corpus luteum. Endocrinology. 1991 Oct; 129(4):1821-30. PMID: 1833177.
      View in: PubMed
    90. Barbieri FD, Raisman JS, Albarracin C. Amylase and glycogenolysis in amphibian development. Biol Bull. 1967 Jun; 132(3):299-310. PMID: 6068944.
      View in: PubMed
    91. Rare Malignant Tumors of the Breast. Journal of Clinical Imaging Science. 5.
    92. Pseudoangiomatous Stromal Hyperplasia of the Breast. Current Problems in Diagnostic Radiology.
    93. Erratum to. Breast Cancer Research. 17.
    94. The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clinical Cancer Research. 21:2580-2590.
    95. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research. 16.
    96. Annexin A1 preferentially predicts poor prognosis of basal-like breast cancer patients by activating mTOR-S6 signaling. PLoS One. 10.
    97. Multi-institutional comparison of Whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sections. Archives of Pathology and Laboratory Medicine. 137:1733-1739.
    98. Ki67 as a Biomarker of Prognosis and Prediction. Current Breast Cancer Reports. 6:260-266.
    99. Erratum. Cancer. 120:927.
    100. Immunological and molecular studies in breast tumors. 209-243.
    101. Erratum. Breast Cancer Research and Treatment. 89:95.
    102. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Modern Pathology.
    103. Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Annals of Surgical Oncology. 1-7.
    104. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Breast Diseases. 22:383-384.
    ALBARRACIN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description